Spectral Medical (FRA:SD4) Risk Assessment

View and export this data going back to 2013. Start your Free Trial

What is Spectral Medical Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Spectral Medical is: High Risk: High uncertainty with risk-return tradeoff.

Competitive Comparison of Spectral Medical's Risk Assessment

For the Diagnostics & Research subindustry, Spectral Medical's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spectral Medical's Risk Assessment Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Spectral Medical's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Spectral Medical's Risk Assessment falls into.

Spectral Medical (FRA:SD4) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Spectral Medical Risk Assessment Related Terms

Thank you for viewing the detailed overview of Spectral Medical's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Spectral Medical (FRA:SD4) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Spectral Medical Inc (FRA:SD4) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

EDTXF:USA EDT:Canada

Address

135 - 2 The West Mall, Finance, Toronto, ON, CAN, M9C 1C2

Website

https://www.spectraldx.com

Spectral Medical Inc is focused on the development and commercialization of a treatment for septic shock utilizing its endotoxin activity assay (EAA) diagnostic and the toraymyxin therapeutic. The company also manufactures and sells proprietary reagents. The product line of the company consists of proprietary biochemical, EAA, and instrumentation. The company has one reporting segment Spectral Medical Inc. The Dialco Medical Inc. operations were considered discontinued by the company.

Spectral Medical (FRA:SD4) Headlines

No Headlines